Esperion Therapeutics Files 8-K: Director Changes & Compensation Updates
Ticker: ESPR · Form: 8-K · Filed: Jun 2, 2025 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | 8-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
Related Tickers: ESPR
TL;DR
Esperion Therapeutics (ESPR) filed an 8-K detailing director changes and compensation adjustments.
AI Summary
Esperion Therapeutics, Inc. filed an 8-K on May 29, 2025, reporting on the departure of a director, election of a new director, and changes in officer compensation. The filing also covers matters submitted to a vote of security holders and includes financial statements and exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is routine corporate disclosure and does not appear to contain significant negative or positive financial news.
Key Players & Entities
- Esperion Therapeutics, Inc. (company) — Registrant
- May 29, 2025 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of incorporation
- 3891 Ranchero Drive, Suite 150 (address) — Principal executive offices
- Ann Arbor, MI (location) — City, State of principal executive offices
- 48108 (zip_code) — Zip code of principal executive offices
- ( 734 ) 887-3903 (phone_number) — Registrant's telephone number
FAQ
What specific items were reported under 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'?
The filing indicates a departure of a director, the election of a new director, and changes related to the compensatory arrangements of certain officers.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated May 29, 2025.
What is the principal executive office address of Esperion Therapeutics, Inc.?
The principal executive offices are located at 3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108.
What is the Commission File Number for Esperion Therapeutics, Inc.?
The Commission File Number is 001-35986.
What other types of information are included in this 8-K filing besides officer and director changes?
The filing also includes information on 'Submission of Matters to a Vote of Security Holders' and 'Financial Statements and Exhibits'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 2, 2025 regarding Esperion Therapeutics, Inc. (ESPR).